Clinical Trial Update: BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating adding mitomycin C to Bacillus Calmette-Guérin for high-risk non-muscle-invasive bladder cancer; the trial is currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (Bacillus Calmette-Guérin)
• Mitomycin-C (mitomycin C)

Snippet

Sponsor: Nottingham University Hospitals NHS Trust | Conditions: Transitional Cell Carcinoma, Transurethral Resection | Phase 3 | Status: ACTIVE_NOT_RECRUITING